Cytotoxic and radiosensitising effects of a novel thioredoxin reductase inhibitor in breast cancer.

ABSTRACT: Radiotherapy is an effective treatment modality for breast cancer but, unfortunately, not all patients respond fully with a significant number experiencing local recurrences. Overexpression of thioredoxin and thioredoxin reductase has been reported to cause multidrug and radiation resistance - their inhibition may therefore improve therapeutic efficacy. Novel indolequinone compounds have been shown, in pancreatic cancer models, to inhibit thioredoxin reductase activity and exhibit potent anticancer activity. The present study evaluates, using in vitro breast cancer models, the efficacy of a novel indolequinone compound (IQ9) as a single agent and in combination with ionising radiation using a variety of endpoint assays including cell proliferation, clonogenic survival, enzyme activity, and

SUBMITTER: Abdullah NA 

PROVIDER: S-EPMC8426295 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature